NEOSTIGMINE METHYLSULFATE

N/A

Manufactured by Exela Pharma Sciences, LLC

959 FDA adverse event reports analyzed

Last updated: 2026-04-15

About NEOSTIGMINE METHYLSULFATE

NEOSTIGMINE METHYLSULFATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Exela Pharma Sciences, LLC. The most commonly reported adverse reactions for NEOSTIGMINE METHYLSULFATE include DRUG INEFFECTIVE, ABDOMINAL DISTENSION, HYPOTENSION, NAUSEA, CARDIAC ARREST. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for NEOSTIGMINE METHYLSULFATE.

Top Adverse Reactions

DRUG INEFFECTIVE53 reports
ABDOMINAL DISTENSION26 reports
HYPOTENSION26 reports
NAUSEA23 reports
CARDIAC ARREST21 reports
ABDOMINAL PAIN20 reports
RESPIRATORY FAILURE20 reports
WHITE BLOOD CELL COUNT INCREASED18 reports
PYREXIA16 reports
BRADYCARDIA15 reports
GENERALISED TONIC CLONIC SEIZURE15 reports
SUBILEUS15 reports
FEBRILE NEUTROPENIA14 reports
PULMONARY OEDEMA14 reports
RENAL ISCHAEMIA14 reports
TACHYCARDIA14 reports
ABDOMINAL TENDERNESS13 reports
DEMENTIA13 reports
GASTROINTESTINAL SOUNDS ABNORMAL13 reports
ILEUS13 reports
NECROTISING COLITIS13 reports
PANCREATITIS13 reports
VASCULAR ENCEPHALOPATHY13 reports
DYSPNOEA12 reports
FAECALOMA12 reports
HYPOXIA12 reports
ANAEMIA11 reports
SINUS TACHYCARDIA11 reports
STRESS CARDIOMYOPATHY11 reports
ABDOMINAL MASS10 reports
ASTHENIA10 reports
BLADDER DISORDER10 reports
BLOOD GLUCOSE INCREASED10 reports
CARDIAC DISORDER10 reports
DRUG INTERACTION10 reports
GENERAL PHYSICAL HEALTH DETERIORATION10 reports
HYPERTENSION10 reports
OXYGEN SATURATION DECREASED10 reports
PARALYSIS10 reports
URINARY RETENTION10 reports
BLOOD TEST ABNORMAL9 reports
CHROMATURIA9 reports
CONDITION AGGRAVATED9 reports
FLATULENCE9 reports
HAEMOPERITONEUM9 reports
IMMUNOSUPPRESSION9 reports
RASH9 reports
URINE ABNORMALITY9 reports
DISEASE PROGRESSION8 reports
NEUROMUSCULAR BLOCK PROLONGED8 reports
OFF LABEL USE8 reports
PRODUCT PACKAGING CONFUSION8 reports
PRODUCT USE IN UNAPPROVED INDICATION8 reports
ATRIOVENTRICULAR BLOCK7 reports
CEREBRAL HAEMORRHAGE FOETAL7 reports
CHOLINERGIC SYNDROME7 reports
GASTRIC DILATATION7 reports
LARYNGOSPASM7 reports
LYMPHOCYTE COUNT DECREASED7 reports
PRODUCT LABEL CONFUSION7 reports
PRODUCT QUALITY ISSUE7 reports
SCHIZENCEPHALY7 reports
TORSADE DE POINTES7 reports
ABORTION INDUCED6 reports
BLOOD PRESSURE DECREASED6 reports
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR6 reports
DIARRHOEA6 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION6 reports
DYSTONIA6 reports
FATIGUE6 reports
HAEMOGLOBIN DECREASED6 reports
METABOLIC ENCEPHALOPATHY6 reports
NEUTROPHIL COUNT INCREASED6 reports
ACUTE PULMONARY OEDEMA5 reports
ALOPECIA5 reports
ANAPHYLACTIC SHOCK5 reports
BLOOD UREA INCREASED5 reports
CHEST PAIN5 reports
COUGH5 reports
DIZZINESS5 reports
GAIT DISTURBANCE5 reports
INTESTINAL OBSTRUCTION5 reports
MUSCULAR WEAKNESS5 reports
PARKINSON^S DISEASE5 reports
PLATELET COUNT DECREASED5 reports
POST PROCEDURAL COMPLICATION5 reports
TREATMENT FAILURE5 reports
WEIGHT DECREASED5 reports
ACUTE KIDNEY INJURY4 reports
ALTERED STATE OF CONSCIOUSNESS4 reports
ANXIETY4 reports
ASPARTATE AMINOTRANSFERASE INCREASED4 reports
BLOOD ALBUMIN DECREASED4 reports
BLOOD CALCIUM DECREASED4 reports
BRONCHOSPASM4 reports
CARDIAC HYPERTROPHY4 reports
ELECTROCARDIOGRAM QT PROLONGED4 reports
HEADACHE4 reports
HYPOAESTHESIA4 reports
INTESTINAL PSEUDO OBSTRUCTION4 reports

Report Outcomes

Out of 421 classified reports for NEOSTIGMINE METHYLSULFATE:

Serious 87.2%Non-Serious 12.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female183 (54.6%)
Male141 (42.1%)
Unknown11 (3.3%)

Reports by Age

Age 4624 reports
Age 6818 reports
Age 5714 reports
Age 7311 reports
Age 208 reports
Age 348 reports
Age 388 reports
Age 448 reports
Age 478 reports
Age 768 reports
Age 407 reports
Age 567 reports
Age 587 reports
Age 626 reports
Age 636 reports
Age 666 reports
Age 746 reports
Age 786 reports
Age 65 reports
Age 135 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with NEOSTIGMINE METHYLSULFATE?

This profile reflects 959 FDA FAERS reports that mention NEOSTIGMINE METHYLSULFATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for NEOSTIGMINE METHYLSULFATE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, ABDOMINAL DISTENSION, HYPOTENSION, NAUSEA, CARDIAC ARREST, ABDOMINAL PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures NEOSTIGMINE METHYLSULFATE?

Labeling and FAERS entries often list Exela Pharma Sciences, LLC in connection with NEOSTIGMINE METHYLSULFATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.